US Stock MarketDetailed Quotes

PGEN Precigen

Watchlist
  • 1.310
  • -0.050-3.68%
Close Apr 17 16:00 ET
  • 1.330
  • +0.020+1.53%
Post 17:39 ET
326.08MMarket Cap-3358P/E (TTM)

About Precigen Company

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Company Profile

SymbolPGEN
Company NamePrecigen
Listing DateSep 25, 2018
Issue Price16.00
Founded1998
CEODr. Helen Sabzevari, PhD
MarketNASDAQ
Employees202
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address20374 Seneca Meadows Parkway
CityGermantown
ProvinceMaryland
CountryUnited States of America
Zip Code20876
Phone1-301-556-9900

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Helen Sabzevari, PhD
  • Director and Chief Executive Officer, PGEN Therapeutics, Inc.
  • 3.50M
  • Rutul R. Shah
  • Chief Operating Officer
  • 793.08K
  • Harry Thomasian, Jr
  • Chief Financial Officer and Principal Accounting Officer
  • 886.42K
  • Donald P. Lehr
  • Chief Legal Officer
  • 991.30K
  • Jeffrey Thomas Perez
  • Senior Vice President, Intellectual Property Affairs
  • 898.65K
  • Randal J. Kirk
  • Executive Chairman of the Board
  • 600.00K
  • Fred Hassan
  • Independent Director
  • 306.50K
  • Steven Frank
  • Independent Director
  • 300.00K
  • Dean Jonathan Mitchell
  • Independent Director
  • 306.50K
  • Cesar L. Alvarez
  • Independent Director
  • 312.50K
  • James S. Turley
  • Independent Director
  • 312.50K
  • Vinita D. Gupta
  • Independent Director
  • 306.50K
  • Jeffrey B. Kindler, Esq.
  • Independent Director
  • 319.00K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg